Article info
PDFCommentary
Redefining mental invasiveness in psychiatric treatments: insights from schizophrenia and depression therapies
- Correspondence to Mr Craig Waldence McFarland, Harvard Medical School Center for Bioethics, Harvard University, Cambridge, MA 02138, USA; craigmcfarland{at}college.harvard.edu
Citation
Redefining mental invasiveness in psychiatric treatments: insights from schizophrenia and depression therapies
Publication history
- Received November 16, 2023
- Accepted December 23, 2023
- First published December 28, 2023.
Online issue publication
March 20, 2024
Article Versions
- Previous version (20 March 2024).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Neuropsychiatric syndromes of multiple sclerosis
- Diagnosis and management of bipolar disorders
- Prevalence and major risk factors of type 2 diabetes mellitus among adult psychiatric inpatients from 2005 to 2018 in Beijing, China: a longitudinal observational study
- Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis
- Management of psychotropic drugs during pregnancy
- Bipolar depression: a review of treatment options
- Review on the current use of antipsychotic drugs in children and adolescents
- Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial
- Prescribing pattern of antipsychotic medication for first-episode psychosis: a retrospective cohort study
- Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks?